Navigation Links
Frost & Sullivan Presents CorMatrix Cardiovascular Inc. with 2008 Healthcare Innovation Award for the Treatment of Cardiovascular Disease
Date:11/13/2008

ATLANTA, Nov. 13 /PRNewswire/ -- CorMatrix Cardiovascular Inc., an Atlanta-based company dedicated to developing and delivering unique extracellular matrix (ECM(TM)) biomaterial devices that harness the body's innate ability to repair damaged cardiovascular tissue, announced today that the company was awarded the 2008 Frost & Sullivan Healthcare Innovation Award in the treatment of cardiovascular disease.

The award recognizes CorMatrix's contribution to the cardiovascular market through its involvement in the research, development and marketing of its ECM Technology(TM) for pericardial closure and cardiac tissue repair.

"Frost & Sullivan acknowledges CorMatrix's dedication in the development of the unique ECM Technology(TM). Through this unique technology the company strives to meet the ever growing demand and continuous innovation that characterizes the cardiac device market," said Frost & Sullivan industry analyst Archana Swathy. "This exceptional product enhances the patient's recovery after surgery by facilitating efficient tissue repair."

The company's ECM Technology(TM) product acts as a scaffold into which the patient's own cells migrate and integrate, stimulating the body's innate wound-healing mechanisms to repair tissue at the site of implantation. As the patient's cells populate the matrix, they lay down their own collagen, which matures over time to form a functional tissue repair. The implanted ECM material is gradually replaced and resorbed by the body as the patient's tissue is remodeled.

"We are honored to be presented with this Award, as the recognition further validates the increasing interest and acceptance that our ECM Technology(TM) continues to receive within the clinical community," commented Beecher Lewis, President and Chief Operating Officer of CorMatrix Cardiovascular.

The use of extracellular matrix technology in non-cardiovascular applications has established a significant foothold in soft tissue repair, wound management and orthopedic applications. Since the launch of CorMatrix's ECM for Pericardial Closure, the technology has been used at more than 220 hospitals across the U.S. and has been implanted in more than 9,000 cardiac procedures.

About CorMatrix ECM Technology(TM)

CorMatrix Cardiovascular holds an exclusive license from Purdue University to research, develop, manufacture and market naturally occurring ECM products for cardiovascular applications. The company currently has U.S. clearance and European approval with a CE Mark to market its ECM Technology as an implant for pericardial closure, clearance in the U.S. for cardiac tissue repair, and is conducting preclinical studies on a number of cardiovascular applications including an emulsified, injectible form of its ECM Technology as a potential treatment for heart failure.

About CorMatrix Cardiovascular, Inc.

CorMatrix Cardiovascular, a privately held company based in Atlanta, Georgia, is dedicated to developing and delivering innovative biomaterial devices that harness the body's own innate ability to regenerate damaged heart tissue. For more information visit http://www.cormatrix.com.


'/>"/>
SOURCE CorMatrix Cardiovascular Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Aposense Receives Frost & Sullivan Technology Innovation of the Year Award
2. Frost & Sullivan Awards Genpathway 2008 Healthcare Innovation Award
3. Innovation and Strong Therapeutic Potential Seen in Adult Stem Cells, According to Frost & Sullivan
4. Frost & Sullivan Acknowledges ISTO Technologies Role in Developing Advanced Biologic Products for Bone Healing
5. Small Animal Imaging Market: Biospace Lab Wins Frost & Sullivan Accolade for Its Successful Product Line Strategy
6. Celsis Receives Frost & Sullivan 2008 Best Practices Award
7. ESA Receives 2008 Frost & Sullivan North American Technology Innovation Award for Development of Integrated Metabolomics Systems
8. Frost & Sullivan Recognizes Kionixs Dominance in the MEMS Accelerometers Market Through Product Line Strategy
9. Vascular Biogenics Ltd. Presented With the Frost & Sullivan 2008 European Gene Expression Targeting Platform Technology Innovation Award
10. Athera Biotechnology Founder Johan Frostegard and His Colleagues Win NACB Distinguished Abstract Award at AACC 2008
11. Exiqon Receives the 2008 Frost & Sullivan Growth Strategy Leadership Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Global demand for ... percent through 2020 to $7.2 billion.  This market ... beverages, cleaning products, biofuel production, animal feed, and ... diagnostics, and biocatalysts). Food and beverages will remain ... by increasing consumption of products containing enzymes in ...
(Date:6/27/2016)... June 27, 2016  Sequenom, Inc. (NASDAQ: ... healthier lives through the development of innovative products and ... the United States denied its petition ... claims of Sequenom,s U.S. Patent No. 6,258,540 (",540 Patent") ... established by the Supreme Court,s Mayo Collaborative Services v. ...
(Date:6/27/2016)... CA (PRWEB) , ... June 27, 2016 , ... ... for clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT ... care circle with the physician and clinical trial team. , Using the CONSULT module, ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. ... the faculty of the University of North Carolina Kenan-Flagler Business School ... entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, leading ...
Breaking Biology Technology:
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
(Date:3/31/2016)... March 31, 2016   ... or the "Company") LegacyXChange is excited to ... its soon to be launched online site for trading ... ) will also provide potential shareholders a sense ... technology to an industry that is notorious for fraud. ...
Breaking Biology News(10 mins):